Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria

Vaccine

Volumn 33, Issue 25, 2015, Pages 2851-2857

  Mo, Annie X Y ^a   Pesce, John ^a   Hall, B Fenton ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Immunology; Malaria; Plasmodium falciparum; Sporozoite; Vaccine

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; GAMMA INTERFERON; MALARIA VACCINE; SPOROZOITE VACCINE; T LYMPHOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL IMMUNOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GAMMA DELTA T LYMPHOCYTE; GENE DELETION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOPROPHYLAXIS; INNATE IMMUNITY; INOCULATION; LIVER CELL; MACROPHAGE; MALARIA FALCIPARUM; MEROZOITE; MOSQUITO BITE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM BERGHEI; PRIORITY JOURNAL; PROTEIN MICROARRAY; VACCINATION; WORKSHOP; ANIMAL; IMMUNOLOGY; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RADIATION RESPONSE; SPOROZOITE;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPOROZOITES; VACCINATION;

EID: 84929515367     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.056     Document Type: Conference Paper

References (42)

1. WHO WHO world malaria report 2014, WHO, http://www.who.int/malaria/publications/world_malaria_report_2014/en/.
2. Olotu A., Fegan G., Wambua J., Nyangweso G., Awuondo K., Leach A., et al. Four-year Efficacy of RTS,S/AS01E and Its Interaction with malaria exposure. N Engl J Med 2013, 368:1111-1120.
3. Seder R., Chang L., Enama M., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341(Sep (6152)):1359-1365.
4. Roestenberg M., O'Hara G.A., Duncan C.J.A., Epstein J.E.4, Edwards N.J., Scholzen A., et al. Comparison of clinical and parasitological data from controlled human malaria infection. Trials PLoS ONE 2012, 7(6):e38434.
5. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11(1):57-64.
6. Teirlinck A.C., McCall M.B., Roestenberg M., Scholzen A., Woestenenk R., de Mast Q., et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog 2011, 7(12):e1002389. (Epub 2011 Dec 1).
7. Nahrendorf W., Scholzen A., Bijker E.M., Teirlinck A.C., Bastiaens G.J., Schats R., et al. Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis 2014, 210(12):1981-1990.
8. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E.R., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91(3):471-480.
9. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(Jul (5)):468-477.
10. Roestenberg M., Teirlinck A.C., McCall M.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377(May (9779)):1770-1776. (Epub 2011 Apr 22).
11. Felgner P.L., Roestenberg M., Liang L., Hung C., Jain A., Pablo J., et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep 2013, 3(Dec):3549.
12. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013, 110(May (19)):7862-7867. (Epub 2013 Apr 18).
13. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis 2014, 210(Nov (10)):1605-1615.
14. + T cell immunity. Science 2011, 334(Oct (6055)):475-480. (Epub 2011 Sep 8).
15. Molina D.M., Felgner J., Liang X., Jain A., Hung C., Felgner P., et al. Antibodies against CSP and MSP5 predict irradiated sporozoite vaccine mediated protection against malaria. ASTMH meeting 2013, (Abstract #223, appended).
16. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31(Oct (43)):4975-4983.
17. Finney O.C., Keitany G.J., Smithers H., Kaushansky A., Kappe S., Wang R. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Vaccine 2014, 32(Apr (19)):2135-2138. (Epub 2014 Feb 28).
18. Mikolajczak S.A., Lakshmanan V., Fishbaugher M., Camargo N., Harupa A., Kaushansky A., et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 2014, 22(9):1707-1715.
19. van Schaijk B.C., Ploemen I.H., Annoura T., Vos M.W., Lander F., van Gemert G.J., et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife 2014, 3(Nov). 10.7554/eLife.03582.
20. Nussenzweig R.S., Vanderberg J., Most H., Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216(Oct (5111)):160-162.
21. Jin Y., Kebaier C., Vanderberg J. Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun 2007, 75(11):5532-5539. (Epub 2007 Sep 4).
22. Gueirard P., Tavares J., Thiberge S., Bernex F., Ishino T., Milon G., et al. Development of the malaria parasite in the skin of the mammalian host. Proc Natl Acad Sci USA 2010, 107(Oct (43)):18640-18645. (Epub 2010 Oct 4).
23. Vanderberg J.P., Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 2004, 34(Aug (9)):991-996.
24. Amino R1, Thiberge S., Shorte S., Frischknecht F., Ménard R. Quantitative imaging of Plasmodium sporozoites in the mammalian host. CR Biol 2006, 329(11):858-862. (Epub 2006 Aug 17).
25. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated P. falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
26. Shin S.C., Vanderberg J.P., Terzakis J.A. Direct infection of hepatocytes by sporozoites of Plasmodium berghei. J Protozool 1982, 29(Aug (3)):448-454.
27. Liehl P., Zuzarte-Luís V., Chan J., Zillinger T., Baptista F., Carapau D., et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med 2014, 20(1):47-53.
28. Schmidt N.W., Podyminogin R.L., Butler N.S., Badovinac V.P., Tucker B.J., Bahjat K.S., et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci USA 2008, 105(Sep (37)):14017-14022.
29. Schmidt N.W., Butler N.S., Badovinac V.P., Harty J.T. Extreme CD8 T cell requirements for anti-malarial liver stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 2010, 6(7):e1000998.
30. Howland S.W., Poh C.M., Gun S.Y., Claser C., Malleret B., Shastri N., et al. Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria. EMBO Mol Med 2013, 5(7):916-931.
31. Lau L.S., Fernandez-Ruiz D., Mollard V., Sturm A., Neller M.A., Cozijnsen A., et al. CD8+ T cells from a novel T cell receptor transgenic mouse induce liver-stage immunity that can be boosted by blood-stage infection in rodent malaria. PLoS Pathog 2014, 10(5):e1004135.
32. + T cell responses to malaria liver stages by genome-wide epitope profiling. PLoS Pathog 2013, 9(5):e1003303.
33. Romero P1, Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989, 341(Sep (6240)):323-326.
34. Li X., Fujio M., Imamura M., Wu D., Vasan S., Wong C.H., et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA 2010, 107(29):13010-13015.
35. Padte N.N., Boente-Carrera M., Andrews C.D., McManus J., Grasperge B.F., Gettie A., et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS ONE 2013, 8(10):e78407.
36. Chen X., Wang J., Shah D., Wu M.X. An update on the use of laser technology in skin vaccination. Expert Rev Vaccines 2013, 12(11):1313-1323.
37. Vaughan A.M., Kappe S.H., Ploss A., Mikolajczak S.A. Development of humanized mouse models to study human malaria parasite infection. Future Microbiol 2012, 7(5):657-665.
38. Limbach K., Aguiar J., Gowda K., Patterson N., Abot E., Sedegah M., et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar J 2011, 10(Mar):65.
39. Grubaugh D., Flechtner J.B., Higgins D.E. Proteins as T cell antigens: methods for high-throughput identification. Vaccine 2013, 31(Aug (37)):3805-3810.
40. Chaussabel D., Baldwin N. Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol 2014, 14(4):271-280.
41. Li S., Rouphael N., Duraisingham S., Romero-Steiner S., Presnell S., Davis C., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014, 15(2):195-204.
42. Obermoser G., Presnell S., Domico K., Xu H., Wang Y., Anguiano E., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38(4):831-844.